ProPhase Labs, Inc. Shares Granted, Value, Share-based Payment Arrangement, after Forfeiture
ProPhase Labs, Inc. (PRPH) reported Shares Granted, Value, Share-based Payment Arrangement, after Forfeiture of $500.00 thousand for the 12-month period ending 2011-12-31, per its 10-K filed 2012-03-07.
Discontinued › Shareholders' Equity › Shares Granted, Value, Share-Based Payment Arrangement, after Forfeiture
us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation · last filed 2012-03-07
- ProPhase Labs, Inc. shares granted, value, share-based payment arrangement, after forfeiture for the quarter ending 2011-12-31 was $379.00K.
- ProPhase Labs, Inc. shares granted, value, share-based payment arrangement, after forfeiture for the quarter ending 2011-09-30 was $40.00K.
- ProPhase Labs, Inc. shares granted, value, share-based payment arrangement, after forfeiture for fiscal 2011 was $500.00K, a 455.56% increase from fiscal 2010.
- ProPhase Labs, Inc. shares granted, value, share-based payment arrangement, after forfeiture for fiscal 2010 was $90.00K.
| Period end | Shares Granted, Value, Share-based Payment Arrangement, after Forfeiture 3 month | Shares Granted, Value, Share-based Payment Arrangement, after Forfeiture 6 month | Shares Granted, Value, Share-based Payment Arrangement, after Forfeiture 9 month | Shares Granted, Value, Share-based Payment Arrangement, after Forfeiture 12 month |
|---|---|---|---|---|
| 2011-12-31 | $379.00K derived: 10-K 12 month − 10-Q 9 month · filed 2012-03-07 | $419.00K derived: sum of 2 quarters · filed 2012-03-07 | $500.00K 10-K · filed 2012-03-07 | |
| 2011-09-30 | $40.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-14 | $121.00K 10-Q · filed 2011-11-14 | ||
| 2011-06-30 | $81.00K 10-Q · filed 2011-08-12 | |||
| 2010-12-31 | $90.00K 10-K · filed 2012-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |